01:55 , Oct 13, 2018 |  BioCentury  |  Product Development

Bourla’s breadcrumbs to value

Incoming CEO Albert Bourla has spent only a few of his 25 years at Pfizer Inc. in the pharma’s innovative drugs business, but there are signs he already has laid the groundwork for innovating how...
07:00 , May 16, 2016 |  BC Week In Review  |  Clinical News

Buprenorphine hemiadipate: Phase I data

Indivior said the open-label, U.K. Phase I RB-EU-14-0001 trial in healthy volunteers showed that oral RBP-6300 did not achieve “the anticipated PK profile in humans to justify proceeding further with this technology.” Indivior plc (LSE:INDV),...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Company News

Capsugel, Pulmatrix deal

Capsugel and Pulmatrix partnered exclusively to develop manufacturing processes for iSPERSE-based therapeutic candidates for pulmonary diseases and to manufacture clinical and commercial batches of those therapeutics. Capsugel will combine its spray drying process development with...
07:00 , May 12, 2014 |  BioCentury  |  Strategy

Build up to break up

Pfizer Inc. continues to give signals that the grand plan is to break itself up, and the reality looks like it absolutely needs AstraZeneca plc 's assets to make it work. Pfizer already has internally...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Company News

Bend Research, Capsugel deal

Capsugel will acquire drug delivery company Bend and integrate the company into Capsugel's Dosage Form Solutions (DFS) business unit. Capsugel said Bend's bioavailability enhancement, particularly its spray-dried dispersion (SDD) technology, will complement Capsugel DFS's existing...
07:00 , Jul 2, 2012 |  BC Week In Review  |  Company News

Capsugel, Quotient Bioresearch deal

Quotient's Quotient Clinical Ltd. will combine its RapidFACT real time clinical manufacturing and testing services with lipid-based formulation capabilities from Capsugel to provide clients with lipid-based formulations of poorly soluble molecules with limited oral bioavailability....
07:00 , Oct 24, 2011 |  BioCentury  |  Finance

Abbott's bit parts

Abbott Laboratories is the latest pharma to hope that splitting up will unlock value. But last week's news that Abbott plans to become two companies - a diversified medical products company and a research-based pharmaceutical...
07:00 , Sep 5, 2011 |  BioCentury  |  Strategy

Back to School: Innovation & collaboration

Since the economic downturn of 2008, doom has become ingrained in the biopharma narrative. According to the mantra, budgets for great science have flatlined. New startups can't find VC money to translate great science because...
07:00 , Aug 8, 2011 |  BC Week In Review  |  Company News

Pfizer, Kohlberg Kravis Roberts deal

Pfizer completed its previously announced sale of its Capsugel business to investment firm Kohlberg Kravis Roberts for about $2.4 billion in cash (see BioCentury, April 11). Pfizer Inc. (NYSE:PFE), New York, N.Y.   Kohlberg Kravis...
07:00 , Apr 11, 2011 |  BC Week In Review  |  Company News

Pfizer, Kohlberg Kravis Roberts deal

Pfizer will sell its Capsugel business to investment firm Kohlberg Kravis Roberts for about $2.4 billion in cash. Capsugel, which provides capsule products, equipment and services, had about $750 million in revenue last year. The...